


CLAIMS

What is claimed is:

5

1. A compound of Formula I



or a pharmaceutically acceptable salt thereof,
wherein:

10

R¹ is independently selected from:

15

- C₅ or C₆ cycloalkyl-(C₁-C₈ alkylenyl);
- Substituted C₅ or C₆ cycloalkyl-(C₁-C₈ alkylenyl);
- C₈-C₁₀ bicycloalkyl-(C₁-C₈ alkylenyl);
- Substituted C₈-C₁₀ bicycloalkyl-(C₁-C₈ alkylenyl);
- 5- or 6-membered heterocycloalkyl-(C₁-C₈ alkylenyl);
- Substituted 5- or 6-membered heterocycloalkyl-(C₁-C₈ alkylenyl);
- 8- to 10-membered heterobicycloalkyl-(C₁-C₈ alkylenyl);
- Substituted 8- to 10-membered heterobicycloalkyl-(C₁-C₈ alkylenyl);
- Phenyl-(C₁-C₈ alkylenyl);
- Substituted phenyl-(C₁-C₈ alkylenyl);
- Naphthyl-(C₁-C₈ alkylenyl);
- Substituted naphthyl-(C₁-C₈ alkylenyl);
- 5- or 6-membered heteroaryl-(C₁-C₈ alkylenyl);
- Substituted 5- or 6-membered heteroaryl-(C₁-C₈ alkylenyl);
- 8- to 10-membered heterobiaryl-(C₁-C₈ alkylenyl);
- Substituted 8- to 10-membered heterobiaryl-(C₁-C₈ alkylenyl);
- Phenyl;
- Substituted phenyl;
- Naphthyl;

20

25

Substituted naphthyl;
5- or 6-membered heteroaryl;
Substituted 5- or 6-membered heteroaryl;
8- to 10-membered heterobiaryl; and
5 Substituted 8- to 10-membered heterobiaryl;

R² is independently selected from:

- H;
C₁-C₆ alkyl;
Phenyl-(C₁-C₈ alkylenyl);
10 Substituted phenyl-(C₁-C₈ alkylenyl);
Naphthyl-(C₁-C₈ alkylenyl);
Substituted naphthyl-(C₁-C₈ alkylenyl);
5- or 6-membered heteroaryl-(C₁-C₈ alkylenyl);
Substituted 5- or 6-membered heteroaryl-(C₁-C₈ alkylenyl);
15 8- to 10-membered heterobiaryl-(C₁-C₈ alkylenyl);
Substituted 8- to 10-membered heterobiaryl-(C₁-C₈ alkylenyl);
Phenyl-O-(C₁-C₈ alkylenyl);
Substituted phenyl-O-(C₁-C₈ alkylenyl);
Phenyl-S-(C₁-C₈ alkylenyl);
20 Substituted phenyl-S-(C₁-C₈ alkylenyl);
Phenyl-S(O)-(C₁-C₈ alkylenyl);
Substituted phenyl-S(O)-(C₁-C₈ alkylenyl);
Phenyl-S(O)₂-(C₁-C₈ alkylenyl); and
Substituted phenyl-S(O)₂-(C₁-C₈ alkylenyl);
25 Each substituted R¹ and R² group contains from 1 to 4 substituents, each
independently on a carbon or nitrogen atom, independently selected from:
C₁-C₆ alkyl;
CN;
CF₃;
30 HO;
(C₁-C₆ alkyl)-O;
(C₁-C₆ alkyl)-S(O)₂;
H₂N;


- (C₁-C₆ alkyl)-N(H);
 (C₁-C₆ alkyl)₂-N;
 (C₁-C₆ alkyl)-C(O)O-(C₁-C₈ alkylenyl)_m;
 (C₁-C₆ alkyl)-C(O)O-(1- to 8-membered heteroalkylenyl)_m;
 5 (C₁-C₆ alkyl)-C(O)N(H)-(C₁-C₈ alkylenyl)_m;
 (C₁-C₆ alkyl)-C(O)N(H)-(1- to 8-membered heteroalkylenyl)_m;
 H₂NS(O)₂-(C₁-C₈ alkylenyl);
 (C₁-C₆ alkyl)-N(H)S(O)₂-(C₁-C₈ alkylenyl)_m;
 (C₁-C₆ alkyl)₂-NS(O)₂-(C₁-C₈ alkylenyl)_m;
 10 3- to 6-membered heterocycloalkyl-(G)_m;
 Substituted 3- to 6-membered heterocycloalkyl-(G)_m;
 5- or 6-membered heteroaryl-(G)_m;
 Substituted 5- or 6-membered heteroaryl-(G)_m;
 (C₁-C₆ alkyl)-S(O)₂-N(H)-C(O)-(C₁-C₈ alkylenyl)_m; and
 15 (C₁-C₆ alkyl)-C(O)-N(H)-S(O)₂-(C₁-C₈ alkylenyl)_m;


wherein each substituent on a carbon atom may further be independently selected from:

Halo; and

HO₂C;

- 20 wherein 2 substituents may be taken together with a carbon atom to which they are both bonded to form the group C=O;
 wherein two adjacent, substantially sp² carbon atoms may be taken together with a diradical substituent to form a cyclic diradical selected from:





R is H or C₁-C₆ alkyl;

5 G is CH₂; O, S, S(O); or S(O)₂;

m is an integer of 0 or 1;

R⁷ is independently selected from the groups:

H;

CH₃;

10 CH₃O;

CH=CH₂;

HO;

CF₃;

CN;

15 HC(O);

CH₃C(O);

HC(NOH);

H₂N;

(CH₃)-N(H);

20 (CH₃)₂-N;

H₂NC(O);

(CH₃)-N(H)C(O);


(CH₃)₂-NC(O);

halo; and

CO₂H;

Y⁶ and Y⁸ are each independently CH₂, C(O), O, S, S(O), S(O)₂, or N(R⁵); or

R⁷ and Y⁸ may be taken together with the carbon atom to which they are both
5 attached to form a group selected from:



R⁴ and R⁵ are each independently selected from the groups:

H;

CH₃;

10 CH₃O;

CH=CH₂;

HO;

CF₃;

CN;

15 HC(O);

CH₃C(O);

HC(NO₂);

H₂N;

(CH₃)-N(H);

20 (CH₃)₂-N;

H₂NC(O);

(CH₃)-N(H)C(O); and

(CH₃)₂-NC(O);

Q is selected from:

25 OC(O);

CH(R⁶)C(O);

OC(NR⁶);

CH(R⁶)C(NR⁶);

N(R⁶)C(O);

30 N(R⁶)C(S);

$N(R^6)C(NR^6)$;

$N(R^6)CH_2$;

$SC(O)$;

$CH(R^6)C(S)$;

5

$SC(NR^6)$;

$trans-(H)C=C(H)$;

$cis-(H)C=C(H)$;

$C\equiv C$;


$CH_2C\equiv C$;

10


$C\equiv CCH_2$;

$CF_2C\equiv C$; and


$C\equiv CCF_2$;




;




;




;




;



;



; and



;

15

Each R^6 independently is H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl; 3- to 6-membered heterocycloalkyl; phenyl; benzyl; or 5- or 6-membered heteroaryl;

X is O, S, N(H), or N(C_1 - C_6 alkyl);

Each V is independently C(H) or N;

20

wherein each C_8 - C_{10} bicycloalkyl is a bicyclic carbocyclic ring that contains 8-, 9-, or 10-member carbon atoms which are 5,5-fused, 6,5-fused, or 6,6-fused bicyclic rings, respectively, and wherein the ring is saturated or optionally contains one carbon-carbon double bond;

wherein each 8- to 10-membered heterobicycloalkyl is a bicyclic ring that contains carbon atoms and from 1 to 4 heteroatoms independently selected from 2

O, 1 S, 1 S(O), 1 S(O)₂, 1 N, 4 N(H), and 4 N(C₁-C₆ alkyl), and wherein when two O atoms or one O atom and one S atom are present, the two O atoms or one O atom and one S atom are not bonded to each other, and wherein the ring is saturated or optionally contains one carbon-carbon or carbon-nitrogen double bond, and wherein the heterobicycloalkyl is a 5,5-fused, 6,5-fused, or 6,6-fused bicyclic ring, respectively,

wherein each heterocycloalkyl is a ring that contains carbon atoms and from 1 to 4 heteroatoms independently selected from 2 O, 1 S, 1 S(O), 1 S(O)₂, 1 N, 4 N(H), and 4 N(C₁-C₆ alkyl), and wherein when two O atoms or one O atom and one S atom are present, the two O atoms or one O atom and one S atom are not bonded to each other, and wherein the ring is saturated or optionally contains one carbon-carbon or carbon-nitrogen double bond;

wherein each 5-membered heteroaryl contains carbon atoms and from 1 to 4 heteroatoms independently selected from 1 O, 1 S, 1 N(H), 1 N(C₁-C₆ alkyl), and 4 N, and each 6-membered heteroaryl contains carbon atoms and 1 or 2 heteroatoms independently selected from N, N(H), and N(C₁-C₆ alkyl), and 5- and 6-membered heteroaryl are monocyclic rings;


wherein each heterobiaryl contains carbon atoms and from 1 to 4 heteroatoms independently selected from 1 O, 1 S, 1 N(H), 1 N(C₁-C₆ alkyl), and 4 N, and where the 8-, 9-, and 10-membered heterobiaryl are 5,5-fused, 6,5-fused, and 6,6-fused bicyclic rings, respectively, and wherein at least 1 of the 2 fused rings of a bicyclic ring is aromatic, and wherein when the O and S atoms both are present, the O and S atoms are not bonded to each other;

wherein with any (C₁-C₆ alkyl)₂-N group, the C₁-C₆ alkyl groups may be optionally taken together with the nitrogen atom to which they are attached to form a 5- or 6-membered heterocycloalkyl; and

wherein each group and each substituent recited above is independently selected.

2. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein each of Y⁶ and Y⁸ is independently CH₂ or S(O)₂.

3. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein R^7 and Y^8 are taken together with the carbon atom to which they are both attached to form a group selected from:



5

4. The compound according to Claim 1, wherein Q is $C\equiv C$.

5. The compound according to Claim 1, wherein Q is $N(R^6)C(O)$.

10 6. The compound according to any one of Claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R^1 is independently selected from:

Phenyl-(C_1 - C_8 alkylenyl);

Substituted phenyl-(C_1 - C_8 alkylenyl);

15 5- or 6-membered heteroaryl-(C_1 - C_8 alkylenyl);

Substituted 5- or 6-membered heteroaryl-(C_1 - C_8 alkylenyl);

8- to 10-membered heterobiaryl-(C_1 - C_8 alkylenyl); and

Substituted 8- to 10-membered heterobiaryl-(C_1 - C_8 alkylenyl); and

R^2 is independently selected from:

20 Phenyl-(C_1 - C_8 alkylenyl)_m;

Substituted phenyl-(C_1 - C_8 alkylenyl)_m;

5- or 6-membered heteroaryl-(C_1 - C_8 alkylenyl)_m;

Substituted 5- or 6-membered heteroaryl-(C_1 - C_8 alkylenyl)_m;


8- to 10-membered heterobiaryl-(C_1 - C_8 alkylenyl)_m; and

25 Substituted 8- to 10-membered heterobiaryl-(C_1 - C_8 alkylenyl)_m;

wherein m is an integer of 0 or 1; and

wherein each group and each substituent is independently selected.

7. The compound according to Claim 1 of Formula II



II

8. The compound according to Claim 7 selected from:

- 5 7-(3,5-Difluoro-4-hydroxy-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;
- 7-Benzyl-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-3-carboxylic acid 3-methoxy-benzylamide;
- 10 7-(3,4-Difluoro-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-3-carboxylic acid (pyridin-4-ylmethyl)-amide;
- 7-Benzyl-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-3-carboxylic acid (pyridin-4-ylmethyl)-amide;
- 15 7-Benzyl-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;
- 7-(3,4-Difluoro-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;
- 20 7-[4-(3-Ethyl-ureido)-benzyl]-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;
- 7-(3,4-Difluoro-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-3-carboxylic acid 4-fluoro-benzylamide;
- 25 6-Benzyl-8-methyl-5,7-dioxo-1,2,4a,5,6,7-hexahydro-2,6-naphthyridine-3-carboxylic acid 4-fluoro-benzylamide;

- 7-(4-Cyano-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-3-carboxylic acid 4-fluoro-benzylamide;
- 5 7-(3,5-Difluoro-4-hydroxy-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]oxazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;
- 7-Benzyl-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]oxazine-3-carboxylic acid 3-methoxy-benzylamide;
- 10 7-(3,4-Difluoro-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]oxazine-3-carboxylic acid (pyridin-4-ylmethyl)-amide;
- 7-Benzyl-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]oxazine-3-carboxylic acid (pyridin-4-ylmethyl)-amide;
- 15 7-Benzyl-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]oxazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;
- 7-(3,4-Difluoro-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]oxazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;
- 20 7-[4-(3-Ethyl-ureido)-benzyl]-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]oxazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;
- 7-(3,4-Difluoro-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]oxazine-3-carboxylic acid 4-fluoro-benzylamide;
- 25 6-Benzyl-8-methyl-5,7-dioxo-4a,5,6,7-tetrahydro-1H-pyrano[4,3-c]pyridine-3-carboxylic acid 4-fluoro-benzylamide;
- 7-(4-Cyano-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]oxazine-3-carboxylic acid 4-fluoro-benzylamide;
- 30 7-(3,5-Difluoro-4-hydroxy-benzyl)-9-methyl-2,2,6,8-tetraoxo-1,6,7,8-tetrahydro-2H-2⁶-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

- 7-Benzyl-9-methyl-2,2,6,8-tetraoxo-1,6,7,8-tetrahydro-2H-2 ℓ^6 -
pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid 3-methoxy-
benzylamide;
- 5 7-(3,4-Difluoro-benzyl)-9-methyl-2,2,6,8-tetraoxo-1,6,7,8-tetrahydro-2H-
2 ℓ^6 -pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (pyridin-4-
ylmethyl)-amide;
- 7-Benzyl-9-methyl-2,2,6,8-tetraoxo-1,6,7,8-tetrahydro-2H-2 ℓ^6 -
pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (pyridin-4-
ylmethyl)-amide;
- 10 7-Benzyl-9-methyl-2,2,6,8-tetraoxo-1,6,7,8-tetrahydro-2H-2 ℓ^6 -
pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-
pyridin-4-ylmethyl)-amide;
- 7-(3,4-Difluoro-benzyl)-9-methyl-2,2,6,8-tetraoxo-1,6,7,8-tetrahydro-2H-
2 ℓ^6 -pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-
pyridin-4-ylmethyl)-amide;
- 15 7-[4-(3-Ethyl-ureido)-benzyl]-9-methyl-2,2,6,8-tetraoxo-1,6,7,8-
tetrahydro-2H-2 ℓ^6 -pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid
(2-methoxy-pyridin-4-ylmethyl)-amide;
- 7-(3,4-Difluoro-benzyl)-9-methyl-2,2,6,8-tetraoxo-1,6,7,8-tetrahydro-2H-
2 ℓ^6 -pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid 4-fluoro-
benzylamide;
- 20 6-Benzyl-8-methyl-2,2,5,7-tetraoxo-1,2,4a,5,6,7-hexahydro-2 ℓ^6 -
thiopyrano[4,3-c]pyridine-3-carboxylic acid 4-fluoro-benzylamide;
and
- 25 7-(4-Cyano-benzyl)-9-methyl-2,2,6,8-tetraoxo-1,6,7,8-tetrahydro-2H-2 ℓ^6 -
pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid 4-fluoro-
benzylamide;
- or a pharmaceutically acceptable salt thereof.
- 30 9. The compound according to Claim 7 selected from:
7-(3,5-Difluoro-4-hydroxy-benzyl)-2-hydroxy-9-methyl-6,8-dioxo-1,6,7,8-
tetrahydro-2H-2 ℓ^4 -pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid
(2-methoxy-pyridin-4-ylmethyl)-amide;

- 7-Benzyl-2-hydroxy-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-2I⁴-
pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid 3-methoxy-
benzylamide;
- 5 7-(3,4-Difluoro-benzyl)-2-hydroxy-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-
2H-2I⁴-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (pyridin-4-
ylmethyl)-amide;
- 7-Benzyl-2-hydroxy-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-2I⁴-
pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (pyridin-4-
ylmethyl)-amide;
- 10 7-Benzyl-2-hydroxy-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-2I⁴-
pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-
pyridin-4-ylmethyl)-amide;
- 7-(3,4-Difluoro-benzyl)-2-hydroxy-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-
2H-2I⁴-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-
pyridin-4-ylmethyl)-amide;
- 15 7-[4-(3-Ethyl-ureido)-benzyl]-2-hydroxy-9-methyl-6,8-dioxo-1,6,7,8-
tetrahydro-2H-2I⁴-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid
(2-methoxy-pyridin-4-ylmethyl)-amide;
- 7-(3,4-Difluoro-benzyl)-2-hydroxy-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-
2H-2I⁴-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid 4-fluoro-
benzylamide;
- 20 6-Benzyl-2-hydroxy-8-methyl-5,7-dioxo-1,2,4a,5,6,7-hexahydro-2I⁴-
thiopyrano[4,3-c]pyridine-3-carboxylic acid 4-fluoro-benzylamide;
- 7-(4-Cyano-benzyl)-2-hydroxy-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-
2I⁴-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid 4-fluoro-
benzylamide;
- 25 7-(3,5-Difluoro-4-hydroxy-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-
pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-
pyridin-4-ylmethyl)-amide;
- 30 7-Benzyl-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-
c][1,4]thiazine-3-carboxylic acid 3-methoxy-benzylamide;

7-(3,4-Difluoro-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (pyridin-4-ylmethyl)-amide;

5 7-Benzyl-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (pyridin-4-ylmethyl)-amide;

7-Benzyl-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

10 7-(3,4-Difluoro-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

7-[4-(3-Ethyl-ureido)-benzyl]-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

15 7-(3,4-Difluoro-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid 4-fluoro-benzylamide;

6-Benzyl-8-methyl-5,7-dioxo-4a,5,6,7-tetrahydro-1H-thiopyrano[4,3-c]pyridine-3-carboxylic acid 4-fluoro-benzylamide; and

20 7-(4-Cyano-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid 4-fluoro-benzylamide;
or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition, comprising a compound of Claim 1, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, excipient, or diluent.

11. The pharmaceutical composition according to Claim 10, comprising a compound according to Claim 8 or 9, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, excipient, or diluent.

30

12. A method for treating osteoarthritis or rheumatoid arthritis, comprising administering to a patient suffering from osteoarthritis or rheumatoid arthritis a

nontoxic effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

- 5 13. The method according to Claim 12 wherein the compound of Claim 1 is a compound of Claim 8 or 9.